Showing results (331-340 of 424) with videos related to
Sort By:
Pageof 43
Journal of Hepatology|December 16, 2022
NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learnedDaniel Guldager Kring Rasmussen, Quentin M Anstee, Richard Torstenson, et al.Alimentary Pharmacology & Therapeutics|February 19, 2025
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' PerspectiveZobair M Younossi, Homie Razavi, Michael Sherman, et al.Journal of Hepatology|July 8, 2020
Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis deltaDominique Roulot, Ségolène Brichler, Richard Layese, et al.Gastro Hep Advances|February 17, 2022
Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 InfectionPauline Maisonnasse, Thierry Poynard, Mehdi Sakka, et al.Liver International : Official Journal of the International Association for the Study of the Liver|January 10, 2025
Liver Disease Complicating Familial Mediterranean Fever: A Study on 66 Patients Out of 533 Adult From the JIR CohortMarion Delplanque, Xavier Amiot, Dominique Wendum, et al.Frontiers in Genetics|November 22, 2019
Identification of an Endoglin Variant Associated With HCV-Related Liver Fibrosis Progression by Next-Generation SequencingFrédégonde About, Stéphanie Bibert, Emmanuelle Jouanguy, et al.Gastroenterology|March 23, 2011
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis CJordi Bruix, Thierry Poynard, Massimo Colombo, et al.Journal of Pediatric Gastroenterology and Nutrition|July 29, 2017
Cystic Fibrosis-related Liver Disease: Research Challenges and Future PerspectivesDominique Debray, Michael R Narkewicz, Frank A J A Bodewes, et al.Hepatology (Baltimore, Md.)|October 15, 2014
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virusEric M Yoshida, Mark S Sulkowski, Edward J Gane, et al.Gut|December 28, 2020
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver diseaseMarta B Afonso, Pedro M Rodrigues, Miguel Mateus-Pinheiro, et al.Pageof 43